1. 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). (September 2015) Authors: Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M.S.; Wolter, P.; Lebbé, C.; Schachter, J.; Thomas, L.; Hassel, J.C.; Lorigan, P.; Walker, D.; Jiang, J.; Hodi, F.S.; Wolchok, J.D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma. (September 2015) Authors: Dummer, R.; Sandhu, S.; Hassel, J.C.; Muñoz, E.; Berking, C.; Gesierich, A.; Ascierto, P.A.; Esposito, O.; Carter, K.; Antona, V.; Radhakrishnan, R.; Cui, X.; Caponigro, G.; Jaeger, S.; Demuth, T.; Miller Jr, W.H. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S667 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. (13th April 2020) Authors: Livingstone, E.; Zaremba, A.; Horn, S.; Ugurel, S.; Casalini, B.; Schlaak, M.; Hassel, J.C.; Herbst, R.; Utikal, J.S.; Weide, B.; Gutzmer, R.; Meier, F.; Koelsche, C.; Hadaschik, E.; Sucker, A.; Reis, H.; Merkelbach‐Bruse, S.; Siewert, M.; Sahm, F.; von Deimling, A. Journal: British journal of dermatology Issue: Volume 183:Number 5(2020) Page Start: 928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PD‐1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma. (1st January 2017) Authors: Winkler, J.K.; Bender, C.; Kratochwil, C.; Enk, A.; Hassel, J.C. Journal: British journal of dermatology Issue: Volume 176:Number 1(2017) Page Start: 216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer. (1st February 2017) Authors: Winkler, J.K.; Schneiderbauer, R.; Bender, C.; Sedlaczek, O.; Fröhling, S.; Penzel, R.; Enk, A.; Hassel, J.C. Journal: British journal of dermatology Issue: Volume 176:Number 2(2017) Page Start: 498 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma. (1st November 2020) Authors: Livingstone, E.; Zaremba, A.; Horn, S.; Ugurel, S.; Casalini, B.; Schlaak, M.; Hassel, J.C.; Herbst, R.; Utikal, J.S.; Weide, B.; Gutzmer, R.; Meier, F.; Koelsche, C.; Hadaschik, E.; Sucker, A.; Reis, H.; Merkelbach‐Bruse, S.; Siewert, M.; Sahm, F.; von Deimling, A. Journal: British journal of dermatology Issue: Volume 183:Number 5(2020) Page Start: 928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: Post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma. (December 2022) Authors: Hassel, J.C.; Sarnaik, A.; Chesney, J.; Medina, T.; Hamid, O.; Thomas, S.; Wermke, M.; Domingo-Musibay, E.; Kirkwood, J.M.; Larkin, J.; Weber, J.S.; Arance Fernandez, A.M.; Rodriguez, J.F.; Thomas, I.; Corrie, P.G.; Gontcharova, V.; Wu, X.; Shi, W.; Kluger, H. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. (1st February 2018) Authors: Teramoto, Y.; Keim, U.; Gesierich, A.; Schuler, G.; Fiedler, E.; Tüting, T.; Ulrich, C.; Wollina, U.; Hassel, J.C.; Gutzmer, R.; Goerdt, S.; Zouboulis, C.; Leiter, U.; Eigentler, T.K.; Garbe, C. Journal: British journal of dermatology Issue: Volume 178:Number 2(2018) Page Start: 443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer. (17th October 2016) Authors: Winkler, J.K.; Schneiderbauer, R.; Bender, C.; Sedlaczek, O.; Fröhling, S.; Penzel, R.; Enk, A.; Hassel, J.C. Journal: British journal of dermatology Issue: Volume 176:Number 2(2017) Page Start: 498 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. PD‐1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma. (23rd October 2016) Authors: Winkler, J.K.; Bender, C.; Kratochwil, C.; Enk, A.; Hassel, J.C. Journal: British journal of dermatology Issue: Volume 176:Number 1(2017) Page Start: 216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗